Elias Mossialos

Professor Elias Mossialos

Elias Mossialos is the Cheng Yu Tung Chair in Global Health at the London School of Economics and Political Science (LSE) and serves as the Director of LSE Health. From 2017 to 2020, he was the inaugural Head of the Department of Health Policy at LSE.

His research focuses on health systems and policy, exploring topics such as transformation strategies for health organizations, healthcare regulation, access to healthcare, healthcare quality, healthcare financing, pharmaceutical policies, patient outcomes, antimicrobial resistance (AMR), digital health, and cancer care and policy. Professor Mossialos has created an incentive known as the Options Market for Antibiotics, inspired by financial call options. Additionally, he has devised a financial securitisation mechanism that involves pooling and repackaging of debt. This mechanism aims to enhance the viability of implementing long-term performance-based annuities for funding cell and gene therapies targeted at orphan diseases.

In 2010 he was awarded the Andrija Stampar medal by the Association of Schools of Public Health in Europe (ASPHER) and the European Public Health Association (EUPHA), for contributions to European public health. He received the Choice award by the Association of US College and Research Libraries (ACRL) for Outstanding Academic Title of 2021, the 2002 and 2007 Baxter Awards from the European Health Management Association for the best publication in health policy and management in Europe and the 2022 Helen-Clark-JoPPP Award for Pharmaceutical Policy and Practice Research. In 2009, under his directorship, LSE Health was honoured with the biennial Queen's Anniversary Prize for Higher and Further Education in the UK.

Selected recent publications

Anderson M, Molloy A, Maynou L, Kyriopoulos I, McGuire A, Mossialos E. Evaluation of the NHS England evidence-based interventions programme: a difference-in-difference analysis. BMJ Qual Saf. 2023 Feb;32(2):90-99.

Nikoloski Z, McGuire A, Mossialos E. Evaluation of progress toward universal health coverage in Myanmar: A national and subnational analysis. PLoS Med. 2021 Oct 15;18(10):e1003811. doi: 10.1371/journal.pmed.1003811.

Cherla A, Naci H, Kesselheim AS, Gyawali B, Mossialos E. Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval. JAMA Intern Med. 2021 Apr 1;181(4):490-498.